Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Richard Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, MD, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Daniel Fremgen, Chris Storgard, MD, Abhinav Deol, MD

Blood (2017) 130 (Supplement 1): 4498.

https://doi.org/10.1182/blood.V130.Suppl_1.4498.4498

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

Philippe Armand, MD, PhD, Waleska Perez, MPH, Mei-Jie Zhang, PhD, Haesook Kim, PhD, Thomas R. Klumpp, MD, Paola Dal Cin, PhD, Edmund K Waller, MD, PhD, Mark R. Litzow, MD, Jane L. Liesveld, MD, Hillard M. Lazarus, MD, FACP, Andrew Artz, MD, MS, Vikas Gupta, MD, MRCP, FRCPath, Bipin N. Savani, MD, Philip L. McCarthy, MD, Jean-Yves Cahn, MD, Harry Schouten, Jurgen Finke, MD, Edward D. Ball, MD, Mahmoud Aljurf, MD, Corey Cutler, MD, MPH, FRCPC, Jacob M. Rowe, Joseph H. Antin, MD, Luis M Isola, MD, Paolo Di Bartolomeo, MD, Bruce Camitta, MD, Alan M Miller, MD, PhD, Mitchell S. Cairo, MD, Keith E. Stockerl-Goldstein, MD, Jorge Sierra, MD, Mary Lynn Savoie, MD, FRCPC, Joerg Halter, MD, Patrick J Stiff, MD, Chadi Nabhan, MD, FACP, Ann A. Jakubowski, MD, PhD, Donald Bunjes, MD, Effie W. Petersdorf, MD, Steven M Devine, MD, Richard Maziarz, MD, Martin Bornhauser, MD, Victor A Lewis, MD, David I. Marks, MBBS, PHD, Christopher N Bredeson, MD, MSc, FRCPC, Robert Soiffer, MD, Daniel J. Weisdorf, MD

Blood (2010) 116 (21): 680.

https://doi.org/10.1182/blood.V116.21.680.680

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

Stephanie Lee, MD, Richard Maziarz, MD, Manisha Kukreja, MBBS, MPH, Tao Wang, PhD, Sergio Giralt, MD, Jeffrey Szer, MBBS, Ann Woolfrey, MD, Mukta Arora, MD, MS

Blood (2007) 110 (11): 738.

https://doi.org/10.1182/blood.V110.11.738.738

Published: 2007

Journal Articles

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Andrew R. Rezvani, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael Maris, MD, Edward Agura, MD, Richard Maziarz, MD, James C. Wade, MD, Thomas Chauncey, MD, PhD, Stephen J. Forman, MD, Dietger W. Niederwieser, MD, Judith Shizuru, MD, Amelia Langston, MD, Michael Pulsipher, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2006) 108 (11): 3124.

https://doi.org/10.1182/blood.V108.11.3124.3124

Published: 2006

Journal Articles

Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells

R. Keaney Rathbun, Gregory R. Faulkner, Marika H. Ostroski, Tracy A. Christianson, Grant Hughes, Gary Jones, Robert Cahn, Richard Maziarz, Gordon Royle, Winifred Keeble, Michael C. Heinrich, Markus Grompe, Paula A. Tower, Grover C. Bagby

Blood (1997) 90 (3): 974–985.

https://doi.org/10.1182/blood.V90.3.974

Published: 1997

NARROW

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells

Email alerts

ASH Publications

American Society of Hematology

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only